Leerink Partnrs Issues Negative Estimate for ZNTL Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Research analysts at Leerink Partnrs dropped their Q1 2025 earnings per share (EPS) estimates for shares of Zentalis Pharmaceuticals in a research note issued to investors on Wednesday, March 26th. Leerink Partnrs analyst A. Berens now expects that the company will post earnings of ($0.69) per share for the quarter, down from their prior forecast of ($0.68). The consensus estimate for Zentalis Pharmaceuticals' current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Zentalis Pharmaceuticals' FY2025 earnings at ($2.01) EPS and FY2026 earnings at ($1.82) EPS.

ZNTL has been the subject of a number of other reports. UBS Group reduced their price objective on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating for the company in a report on Tuesday, January 28th. Wells Fargo & Company cut their price target on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating for the company in a research note on Thursday, January 30th. Wedbush reissued a "neutral" rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a report on Friday, March 28th. Finally, HC Wainwright restated a "buy" rating and issued a $10.00 target price on shares of Zentalis Pharmaceuticals in a report on Thursday, March 27th. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $8.24.

Remove Ads

Zentalis Pharmaceuticals Stock Down 5.2 %

ZNTL stock traded down $0.07 during midday trading on Monday, reaching $1.29. 645,349 shares of the company's stock traded hands, compared to its average volume of 1,533,359. The firm's fifty day moving average price is $1.97 and its 200-day moving average price is $2.81. Zentalis Pharmaceuticals has a 52 week low of $1.21 and a 52 week high of $16.21. The company has a market cap of $92.28 million, a price-to-earnings ratio of -0.52 and a beta of 1.75.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last released its quarterly earnings data on Wednesday, March 26th. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.09. The firm had revenue of $26.90 million for the quarter.

Insider Activity

In other Zentalis Pharmaceuticals news, insider Ingmar Bruns acquired 20,000 shares of the business's stock in a transaction on Thursday, February 6th. The shares were acquired at an average price of $2.28 per share, with a total value of $45,600.00. Following the completion of the transaction, the insider now owns 36,629 shares in the company, valued at approximately $83,514.12. This trade represents a 120.27 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Jan Skvarka bought 60,000 shares of the firm's stock in a transaction dated Friday, January 31st. The shares were acquired at an average cost of $1.72 per share, with a total value of $103,200.00. Following the completion of the transaction, the director now owns 149,551 shares in the company, valued at approximately $257,227.72. The trade was a 67.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Corton Capital Inc. bought a new stake in shares of Zentalis Pharmaceuticals in the 4th quarter worth approximately $32,000. Captrust Financial Advisors bought a new stake in shares of Zentalis Pharmaceuticals in the fourth quarter valued at $33,000. Erste Asset Management GmbH bought a new stake in shares of Zentalis Pharmaceuticals in the third quarter valued at $37,000. Paloma Partners Management Co purchased a new position in shares of Zentalis Pharmaceuticals during the 3rd quarter valued at $37,000. Finally, Prudential Financial Inc. bought a new position in shares of Zentalis Pharmaceuticals during the 4th quarter worth $39,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.